

## A Safe and Ensured Prevention of Osteoporosis in Women After Menopause

Perspective Article

Okazaki K\*

Okazaki Medical Clinic, Ukyoku, Kyoto, Japan.

It is well known that the rate of absorption of calcium from bones into blood plasma increases after menopause due to the accompanied decrease in the rate of endogenous secretion of estrogen from ovaries. It is also well known that excessive exogenous supply of estrogen augments the risk-rate of carcinogenesis.

On the other hand, it appears that little is known about a safe and ensured method of prevention of carcinogenesis. As a matter of fact, discovery of a specific cancer drug has been reported as long as 32 years ago [1]. Although the discoverer did not demonstrate the mechanism of action of the stuff, it is highly possible that the stuff inhibits activity of tyrosine kinase, which is the rate-limiting enzyme in the pass-way of carcinogenesis [2]. The basis of this argument is an enzymologically established concept that a chemical compound, of which structure is similar to that of the substrate of the enzyme, exhibits an inhibitory activity towards the enzyme. To be more convincing, the enzyme molecule accepts the inhibitor into its substrate site as an error. Both of tyrosine

and benzaldehyde have benzene nucleus and carbonate radical in common.

### Conclusion

In conclusion, per os intake of both of estrogen and benzoate is the safe and ensured prevention of osteoporosis in women after menopause. In more detail, 0.625mg of estrogen (Premarin; Pfizer) and 250mg of Benfothiamine every 5 days will do the job. As far as the reason why the discovery of the specific cancer drug has not been known widely is concerned, I can't tell anything since I'm not an oncologist.

### References

- [1]. Kochi M (1985) Antitumor Activity of a Benzaldehyde Derivative. *Cancer Treat Rep.* 69(5): 533-537.
- [2]. Okada M, Nakagawa H (1989) A Protein Tyrosine Kinase Involved in Regulation of pp60 Function. *J Biol Chem.* 264(35): 20886-20893.

**\*Corresponding Author:**

Kimihiko Okazaki, MD,  
Okazaki Medical Clinic, Ukyoku, Kyoto, Japan.  
E-mail: ma13081x@ma1.seikyone.jp

**Received:** March 17, 2017**Accepted:** March 22, 2017**Published:** March 23, 2017**Citation:** Okazaki K (2017) A Safe and Ensured Prevention of Osteoporosis in Women After Menopause. *Int J Clin Trials Case Stud.* 2(1), 3.**Copyright:** Okazaki K<sup>©</sup> 2017. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.